Mesoblast (ASX:MSB): The Developments Investors Are Watching After FDA Approval for Ryoncil Potency Assay

Sonal Goyal

24 September 2026 09:49 PM AEST

Mesoblast (ASX:MSB): The Developments Investors Are Watching After FDA Approval for Ryoncil Potency Assay

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Mesoblast received FDA approval for a new potency assay for commercial Ryoncil product release.
The T-cell Proliferation Inhibition BioAssay (TIBA) will support product quality monitoring.
Ryoncil remains the first FDA-approved mesenchymal stromal cell therapy for its indication.
Mesoblast continues developing additional cellular therapies across inflammatory conditions.

Mesoblast Limited (ASX:MSB) is a biotechnology company developing allogeneic, off-the-shelf cellular medicines for severe and life-threatening inflammatory conditions. The company’s proprietary mesenchymal lineage cell therapy platform focuses on reducing inflammatory processes by releasing anti-inflammatory factors that modulate immune responses.

Recent Development

Mesoblast announced on 23 September 2026 that it received approval from the United States Food and Drug Administration (FDA) to implement a new potency assay, known as the T-cell Proliferation Inhibition BioAssay (TIBA), for release and stability monitoring of commercial Ryoncil product lots.

The TIBA assay is designed to detect potential changes in product potency that may occur during Manufacturing process changes or production at new facilities. It will be used alongside existing potency assays measuring IL-2Rα inhibition and CAP (Cell Adhesion and Proliferation) as part of the product release framework under Ryoncil’s Biologics License.

Mesoblast stated that these combined assays are intended to support consistency, potency and clinical effectiveness of Ryoncil commercial batches.

Ryoncil (remestemcel-L-rknd) is the first industrially manufactured allogeneic mesenchymal stromal cell product approved by the FDA for any indication and the only MSC product approved for patients aged two months and older with steroid-refractory acute graft versus host disease (SR-aGvHD).

Sector Context

Mesoblast operates within the biotechnology and regenerative medicine sector, focusing on cellular therapies designed for inflammatory and immune-related conditions.

The company’s lead therapy, Ryoncil, is being developed for additional potential applications, including adult steroid-refractory acute graft versus host disease and biologic-resistant inflammatory bowel disease. Mesoblast is also developing rexlemestrocel-L for potential applications in heart failure and chronic low back pain.

Cell therapy companies operate in a sector where regulatory approvals, manufacturing capabilities, clinical outcomes and commercial adoption are key factors influencing Business development.

Mesoblast has established commercial partnerships in Japan, Europe and China as part of its global development and commercialisation strategy.

The company also maintains a global intellectual property portfolio with more than 1,000 granted patents or Patent applications covering cell compositions, manufacturing methods and therapeutic indications.

Risk and Uncertainty

Mesoblast’s future progress depends on regulatory requirements, manufacturing execution, market adoption and continued development of its cellular therapy pipeline.

The company’s forward-looking activities involve risks associated with clinical development, manufacturing expansion, regulatory approvals, commercialisation activities and reimbursement conditions.

Scaling commercial manufacturing remains an important consideration as Mesoblast expands production capabilities for Ryoncil and evaluates additional indications. The company’s manufacturing processes are designed to produce industrial-scale, cryopreserved, off-the-shelf cellular medicines with defined release criteria.

The biotechnology sector also faces uncertainties related to competition, intellectual property protection, pricing, reimbursement and acceptance of emerging therapies.

Catalysts Investors Can Watch

Future developments for Mesoblast may include commercial progress for Ryoncil, expansion into additional therapeutic indications, manufacturing developments and further regulatory milestones.

The FDA-approved TIBA assay provides an additional quality control measure for commercial Ryoncil production and supports ongoing manufacturing process monitoring.

Investors may also monitor progress across Mesoblast’s broader pipeline, including remestemcel-L applications and rexlemestrocel-L development programs.

The company’s commercial partnerships across Japan, Europe and China may also influence future market expansion opportunities.

Key Takeaways

Mesoblast continues advancing its cellular medicine platform, with FDA approval of the TIBA potency assay supporting commercial Ryoncil manufacturing and quality monitoring. The company remains focused on expanding Ryoncil applications and developing additional cell therapies. Future progress will depend on regulatory execution, manufacturing capabilities, commercial adoption and advancement of its broader pipeline.

FAQs

Q: What does Mesoblast (ASX:MSB) do?

A: Mesoblast develops allogeneic cellular medicines using its proprietary mesenchymal lineage cell therapy technology platform for inflammatory conditions.

Q: What is the FDA-approved TIBA assay?

A: TIBA is a potency assay approved by the FDA for release and stability monitoring of commercial Ryoncil product lots.

Q: What is Ryoncil used for?

A: Ryoncil is an FDA-approved mesenchymal stromal cell therapy for steroid-refractory acute graft versus host disease in patients aged two months and older.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.